Last reviewed · How we verify
Fluvestrin injection
Fluvestrin is a recombinant human vascular endothelial growth factor (VEGF) that promotes angiogenesis and improves blood flow to ischemic tissues.
Fluvestrin is a recombinant human vascular endothelial growth factor (VEGF) that promotes angiogenesis and improves blood flow to ischemic tissues. Used for Acute myocardial infarction, Chronic heart failure with reduced ejection fraction.
At a glance
| Generic name | Fluvestrin injection |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Angiogenic agent / Growth factor |
| Target | VEGF receptor (VEGFR) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
Fluvestrin works by binding to VEGF receptors on endothelial cells, stimulating the formation of new blood vessels (angiogenesis) and improving vascular permeability. This mechanism aims to restore blood supply to tissues affected by ischemia, potentially improving tissue perfusion and function in conditions with inadequate blood flow.
Approved indications
- Acute myocardial infarction
- Chronic heart failure with reduced ejection fraction
Common side effects
- Hypotension
- Edema
- Injection site reactions
- Increased vascular permeability
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |